Travere Therapeutics Submits sNDA To FDA For Approval Of Filspari (Sparsentan) For The Treatment Of FSGS

Reuters
03-17
March 17 (Reuters) - Travere Therapeutics Inc ::
*TRAVERE THERAPEUTICS SUBMITS SNDA TO FDA FOR APPROVAL OF FILSPARI® (SPARSENTAN) FOR THE TREATMENT OF FSGS
*TRAVERE THERAPEUTICS INC: FDA NOTIFIED COMPANY THAT REMS MONITORING FOR EMBRYO-FETAL TOXICITY IS NO LONGER NECESSARY
*TRAVERE THERAPEUTICS INC: PLANS TO SUBMIT AMENDMENT TO REMS SNDA CURRENTLY UNDER REVIEW FOR MODIFICATION OF LIVER MONITORING
*TRAVERE THERAPEUTICS INC: CONTINUES TO EXPECT A REMS MODIFICATION PDUFA TARGET ACTION DATE OF AUGUST 28

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 17-MAR-202511:01:00.21 GMT

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10